A method of delivering a therapeutic agent into and across an endothelial cell in a subject comprising: attaching to a T Cell receptor mimic an active agent to form a therapeutic agent and administering to the subject the therapeutic agent in a pharmaceutically acceptable carrier, wherein the therapeutic agent crosses the endothelial cell microvascular barrier. Currently no specific vascular targets exist. Bevacizumab targets angiogenesis, but no vectors are available for specific targeting of normal or inflamed vascular beds.
A U.S. patent #9,555,108 B2 issued January 31, 2017.
Register for free for full unlimited access to all innovation profiles on LEO
Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
Connect with like-minded individuals and forge valuable relationships and collaboration partners
Innovate together, promote your expertise, or showcase your innovations
